上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

未开盘 11-06 16:08:52

11.360

+0.080

+0.71%

最高11.370	最低11.060	成交量203.95万
今开11.060	昨收11.280	日振幅2.75%
总市值421.23亿	流通市值104.41亿	总股本37.08亿
成交额2,310万	换手率0.22%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.36,"timestamp":1793952532006,"preClose":11.28,"halted":0,"volume":2039461,"delay":0,"changeRate":0.0070921985815602905,"floatShares":919072704,"shares":3708000000,"eps":1.8096032525830574,"marketStatus":"未开盘","change":0.08,"latestTime":"11-06 16:08:52","open":11.06,"high":11.37,"low":11.06,"amount":23101160,"amplitude":0.027482,"askPrice":11.36,"askSize":17400,"bidPrice":11.33,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":1.6333137043633683,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":0,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.28,"dividendRate":0.04661,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.9533675389613705,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.76,"timestamp":1793948400000,"preClose":16.81,"halted":0,"volume":10000000,"delay":0,"premium":"-42.32"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2681849968","title":"上海医药（601607）11月5日主力资金净卖出429.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681849968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681849968?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:34","pubTimestamp":1793925283,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，上海医药报收于16.81元，下跌0.3%，换手率0.51%，成交量14.21万手，成交额2.39亿元。近5日资金流向一览见下表：上海医药融资融券信息显示，融资方面，当日融资买入3020.18万元，融资偿还2454.27万元，融资净买入565.9万元。上海医药主营业务：化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0028","BK0097","BK0188","BK0020","BK0187","02607","BK0175","BK0184","BK0209","BK0196","BK0012","BK0099","BK0183","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681005146","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681005146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681005146?lang=zh_cn&edition=full","pubTime":"2026-11-06 02:06","pubTimestamp":1793901979,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药出资3亿元参与设立的上海上实生物医药产业私募基金已完成私募投资基金备案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600002193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0099","BK0012","161726","BK0028","02607","BK0175","BK0020","BK0097","BK0183","BK0196","BK0209","BK0187","399441","BK0188","BK0184","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681069645","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于参与设立的上海上实生物医药产业私募基金完成私募投资基金备案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681069645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681069645?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:52","pubTimestamp":1793814759,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药出资3亿元参与设立的上海上实生物医药产业私募基金已完成私募投资基金备案。公司公告汇总：子公司上药睿尔收到曲前列尼尔二乙醇胺吸入粉雾剂临床试验批准通知书，该药为2.2类改良型创新药，拟用于治疗肺动脉高压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500003526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0196","BK0184","02607","161726","BK0175","BK0209","BK0183","BK0099","BK0020","BK0097","BK0187","BK1197","601607","399441","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114396372","title":"上海医药(02607)三重动态：15亿元生物医药基金完成备案、控股股东启动最高1% H股增持并获PAH新药临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=1114396372","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114396372?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:05","pubTimestamp":1793790353,"startTime":"0","endTime":"0","summary":"11月5日，上海医药集团股份有限公司连发多份公告，披露在产业基金设立、控股股东增持及创新药研发等方面的最新进展。以下为要点汇总：","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680033020","title":"上海医药(601607.SH)子公司曲前列尼尔二乙醇胺吸入粉雾剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680033020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680033020?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:53","pubTimestamp":1793782399,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药睿尔药品有限公司收到国家药品监督管理局核准签发的关于曲前列尼尔二乙醇胺吸入粉雾剂的《药物临床试验批准通知书》。据悉，曲前列尼尔二乙醇胺吸入粉雾剂为2.2类改良型创新药，活性成分是曲前列尼尔二乙醇胺，为人工合成前列环素类衍生物，拟用于治疗肺动脉高压(PAH，WHO第1组)，以减轻运动引起的相关症状，其作用机制主要通过直接舒张肺和全身动脉血管床并抑制血小板聚集来发挥作用。截至公告披露日，该项目已累计投入研发费用约2141万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","PSYK","MDTX","BK0196","BK0187","BK0209","BK0184","IBBJ","BMED","IBBQ","BK1197","BK0188","601607","BK0175","BK0028","BK0099","BK0183","BK0020","02607","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680795033","title":"上海医药(601607.SH)控股股东拟增持1100万股至2200万股公司H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680795033","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680795033?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:47","pubTimestamp":1793782078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，公司控股股东上海实业(集团)有限公司计划在未来12个月内由其全资子公司上实国际投资有限公司(简称“上实国际”)，通过香港联合交易所有限公司系统以集中竞价方式增持公司H股股份，增持股份总量1100万股至2200万股，不超过公司有投票权股份数的1%。上实国际于2026年11月2日增持公司80万股H股，增持后，上实国际持有公司3.75亿股H股，占公司总股本的10.119%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0012","BK0028","BK0020","BK0183","BK0175","BK0196","BK0209","BK0188","BK0099","601607","BK0184","BK0097","BK1197","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163996558","title":"上海医药10月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1163996558","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163996558?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:45","pubTimestamp":1793695532,"startTime":"0","endTime":"0","summary":"上海医药于2026年11月3日披露2026年10月股份变动月报表。公告显示，截至2026年10月31日，公司注册股本总额为人民币3,708,361,809元，其中H股919,072,704股，A股2,789,289,105股，各类已发行股份数量与上月相比未发生变化。公司在公告中确认，已符合适用的公众持股量要求，并严格遵守香港联合交易所有限公司《上市规则》及相关法律法规。该公告由联席公司秘书钟涛签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680008622","title":"上海医药获得发明专利授权：“GITR结合蛋白及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2680008622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680008622?lang=zh_cn&edition=full","pubTime":"2026-11-02 03:59","pubTimestamp":1793563186,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示上海医药新获得一项发明专利授权，专利名为“GITR结合蛋白及其用途”，专利申请号为CN202210251210.2，授权日为2026年10月30日。专利摘要：本申请涉及一种GITR结合蛋白及其用途，具体涉及一种分离的抗原结合蛋白，包含HCDR3，所述HCDR3包含SEQ ID NO:3所示的氨基酸序列。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0209","BK0099","601607","BK0020","BK0175","BK0187","BK0012","BK0183","BK0097","BK0196","02607","BK0028","BK0188","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679224240","title":"上海医药（601607）2026年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2679224240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679224240?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:22","pubTimestamp":1793416960,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期上海医药发布2026年三季报。根据财报显示，上海医药增收不增利。截至本报告期末，公司营业总收入2229.64亿元，同比上升3.67%，归母净利润45.86亿元，同比下降10.9%。持有上海医药最多的基金为工银创新动力股票，目前规模为11.8亿元，最新净值1.219，较上一交易日下跌0.08%，近一年下跌4.69%。2026年上半年，公司新增进口总代品规16个，实现销售收入超过200亿元，同比增长超15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100023945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0209","BK1197","BK0175","BK0020","BK0196","BK0099","BK0187","BK0183","BK0184","02607","BK0012","BK0188","601607","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679423730","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2679423730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679423730?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:48","pubTimestamp":1793310512,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司关于与上海复旦张江生物医药股份有限公司续签《销售及分销协议》暨日常关联交易的公告2026年10月29日，上海医药与复旦张江续签《销售及分销协议》，有效期自2027年1月1日至2029年12月31日；2027年至2029年每年协议项下销售金额分别不超过8,600万元、9,000万元和9,600万元；交易按市场化定价原则进行，已获公司董事会审议通过，尚需复旦张江股东会批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000008978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","399441","BK0187","688505","02607","BK1197","BK0099","BK1191","BK0175","BK0183","BK0188","161726","BK0097","BK0209","BK0012","BK0028","BK0239","601607","BK0184","BK0020","01349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120694800","title":"上海医药（02607）续签多项关联协议　2027—2029年年度交易上限最高1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120694800","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120694800?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:56","pubTimestamp":1793267764,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司10月30日公告称，公司第九届董事会第六次会议已于2026年10月29日召开并通过多项议案，涉及季度报告审议、关联交易协议续签及内部治理制度等事项。会议应到董事10名，实到10名，表决程序符合《中华人民共和国公司法》和公司章程规定。上海医药与上海复旦张江生物医药股份有限公司续签《销售及分销协议》，期限自2027年1月1日至2029年12月31日。交易金额年度上限均为1亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164773486","title":"上海医药（02607）续签三年房屋租赁框架协议 单年租金上限1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164773486","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164773486?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:56","pubTimestamp":1793267760,"startTime":"0","endTime":"0","summary":"上海医药10月30日公告称，公司已于2026年10月29日与控股股东上海医药（集团）有限公司续签房屋租赁框架协议。新协议自2027年1月1日起至2029年12月31日止，共计三年，将由上药集团持续向公司及其附属公司提供房屋租赁服务。历史数据显示，截至2024年、2025年及2026年6月30日止期间，本集团与上药集团已签署租赁协议对应的使用权资产分别为1,735.11万元、4,767.02万元及1,131.44万元；同期已支付租金分别为3,479.70万元、3,768.21万元及1,850.98万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679179474","title":"上海医药：与上药集团签订房屋租赁框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2679179474","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679179474?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:51","pubTimestamp":1793267460,"startTime":"0","endTime":"0","summary":"南财智讯10月29日电，上海医药（02607.HK）公告，2026年10月29日，公司与上药集团签订房屋租赁框架协议，租赁期限自2027年1月1日起至2029年12月31日止。根据协议，上药集团将向公司提供房屋租赁服务。截至2027年、2028年及2029年12月31日止的三个年度，该协议项下交易的估计最高租金均不超过人民币1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914392242.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914392242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK0028","BK0183","BK0196","BK0209","BK0020","02607","BK0097","601607","BK0012","BK0184","BK0175","BK0099","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128858993","title":"上海医药(02607)披露2026年三季报：前三季度营收2,229.64亿元、经营现金流同比倍增","url":"https://stock-news.laohu8.com/highlight/detail?id=1128858993","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128858993?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:46","pubTimestamp":1793267207,"startTime":"0","endTime":"0","summary":"上海医药(02607)2026年第三季度报告于2026年10月30日发布。报告期内（2026年7月1日至9月30日），公司单季实现营业收入754.94亿元，同比增长2.74%；归属于上市公司股东的净利润为10.82亿元，同比增长57.15%；扣除非经常性损益后净利润为8.97亿元，同比增长49.69%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679847350","title":"上海医药：第三季度归母净利润10.82亿元 同比上升57.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679847350","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679847350?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:34","pubTimestamp":1793262893,"startTime":"0","endTime":"0","summary":"10月29日，上海医药(601607)公布2026年三季报，公司营业收入为2229.64亿元，同比上升3.7%；归母净利润为45.86亿元，同比下降10.9%；扣非归母净利润为33.74亿元，同比上升25.02%；经营现金流净额为53.47亿元，同比增长127.5%；EPS(全面摊薄)为1.24元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914187618.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914187618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678157451","title":"天士力、上海医药等纷纷终止管线研发：同质化竞争下，缺乏差异化跟随管线“及时止损”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678157451","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678157451?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:35","pubTimestamp":1793000109,"startTime":"0","endTime":"0","summary":"数据显示，2025 年全球 HER2 阳性乳腺癌整体抗 HER2 药物市场中，ADC 类药物已占据 41.91% 的市场份额，TKI 仅占 15.02%，且差距仍在持续拉大。总体而言，I025-A的研发进度落后于整体赛道进展，而砍掉一个早期、无差异化优势的TKI项目对于上海医药来说或是一种及时止损。而在10月23日同日，天士力公告终止其化药1类PARP抑制剂TSL-1502胶囊的临床研究开发。除了上述两家公司，2026年以来，国内药企终止管线的案例明显增多。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792999673115111676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["601607","BK0099","BK0239","BK0012","BK0028","02607","600535","BK0020","BK0097","BK0175","BK0183","BK0196","BK0187","BK0209","BK0188","BK0184","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678137984","title":"上海医药：10月23日融资净买入1001.35万元，连续3日累计净买入1394.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678137984","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678137984?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:58","pubTimestamp":1792976280,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日，上海医药(601607)融资买入2199.48万元，融资偿还1198.13万元，融资净买入1001.35万元，融资余额7.27亿元，近3个交易日已连续净买入累计1394.24万元。融券方面，当 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261026/c681063666.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261026/c681063666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0196","601607","BK0097","BK0012","BK0187","BK0188","BK0020","BK0184","BK0099","BK0183","BK0028","BK0175","BK0209","BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136120","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于药品临床试验进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136120?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:50","pubTimestamp":1792954220,"startTime":"0","endTime":"0","summary":"公司公告汇总上海医药集团股份有限公司关于药品临床试验进展的公告上海医药决定终止I025-A研发项目的临床试验及后续开发。上海医药集团股份有限公司关于召开2026年第三季度业绩说明会的公告上海医药将于2026年11月2日10:00–11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0184","02607","BK0012","BK0183","BK0187","BK0175","BK0020","601607","BK0099","BK0028","BK0209","BK1197","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123914227","title":"上海医药（02607）披露三季度业绩说明会安排并终止I025-A临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1123914227","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123914227?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:35","pubTimestamp":1792751742,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司10月24日发布海外监管公告，公布2026年第三季度业绩说明会安排，并同步披露I025-A药品临床试验终止事宜。同日，上海医药公告决定终止I025-A项目的临床试验及后续开发。I025-A为靶向HER2的酪氨酸激酶抑制剂，原拟用于治疗晚期实体瘤。相关研发投入已全部费用化计入相应会计期间损益，本次终止预计不会对公司业绩产生重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677923879","title":"上海医药终止I025-A研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2677923879","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677923879?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:50","pubTimestamp":1792749000,"startTime":"0","endTime":"0","summary":"10月23日，上海医药（601607/02607）发布公告，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止I025-A研发项目。I025-A是靶向HER2的酪氨酸激酶抑制剂（TKI），拟用于晚期实体瘤的治疗。2021年7月，该项目获国家药品监督管理局批准开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906392052.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906392052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0099","BK0184","601607","BK0187","BK0175","02607","BK0188","BK0097","BK0209","BK0028","BK0020","BK0196","BK1197","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.046},{"period":"3month","weight":-0.0327},{"period":"6month","weight":-0.0168},{"period":"1year","weight":0.0178},{"period":"ytd","weight":0.0445}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005809},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014994},{"month":3,"riseRate":0.533333,"avgChangeRate":0.00954},{"month":4,"riseRate":0.533333,"avgChangeRate":0.000637},{"month":5,"riseRate":0.466667,"avgChangeRate":-0.003705},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010272},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010292},{"month":8,"riseRate":0.375,"avgChangeRate":0.007403},{"month":9,"riseRate":0.3125,"avgChangeRate":0.01139},{"month":10,"riseRate":0.3125,"avgChangeRate":-0.019891},{"month":11,"riseRate":0.5,"avgChangeRate":0.029254},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.01256}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}